The clinical impact of hydro-responsive dressings in dynamic wound healing: Part II.

HydroClean HydroTac PUSH score TIME acute chronic debridement epithelialisation hard-to-heal hydro-responsive superabsorbent wound wound bed preparation wound care wound dressing wound healing

Journal

Journal of wound care
ISSN: 0969-0700
Titre abrégé: J Wound Care
Pays: England
ID NLM: 9417080

Informations de publication

Date de publication:
02 Jan 2022
Historique:
entrez: 25 1 2022
pubmed: 26 1 2022
medline: 28 1 2022
Statut: ppublish

Résumé

Over the course of a wound's healing trajectory, whether the wound is acute or hard-to-heal, management is likely to involve the use of several different dressing types. Minimising the complexity of treatment (in terms of dressing usage) would aid clinicians in providing effective wound care but excellent clinical outcomes must remain the primary goal. This study was an open-labelled, non-comparative study assessing the clinical effectiveness of a coordinated wound dressing treatment regimen. After an initial phase of using a hydro-responsive wound dressing (HydroClean, HRWD-1, PAUL HARTMANN AG, Germany) to cleanse and debride hard-to-heal wounds, the wounds were subsequently treated with either HydroTac (HRWD-2, PAUL HARTMANN AG, Germany) (to maintain healing progression and re-epithelialisation) or RespoSorb (a superabsorbent dressing, PAUL HARTMANN AG, Germany) (to manage moderate-to-high levels of exudate). The Pressure Ulcer Scale for Healing (PUSH) assessment tool was used to measure the wound status over the course of the treatment period and to assess several wound status parameters (for example, wound area, exudate levels and wound characteristics such as level of re-epithelialisation). The results from this study demonstrated that wounds treated with HRWD-2 showed a positive healing response when using the PUSH score assessment tool with a significant mean reduction (p<0.0001) in the PUSH score of wounds treated with HRWD-2, with >75% of wounds being closed by the end of the study. This result underlines the effectiveness of HRWD-2 in supporting healing progression. The results from this study support the coordinated use of HRWDs for the effective management and treatment of a variety of hard-to-heal wounds.

Identifiants

pubmed: 35077216
doi: 10.12968/jowc.2022.31.1.56
doi:

Types de publication

Journal Article

Langues

eng

Pagination

56-67

Auteurs

Francois Sterpione (F)

Infirmier, Échirolles, France.

Karine Mas (K)

Perpignan, France.

Mark G Rippon (MG)

University of Huddersfield, Queensgate, Huddersfield, UK.
Medical Marketing Consultant Daneriver Consultancy Ltd, Holmes Chapel, UK.

Alan A Rogers (AA)

Flintshire, North Wales, UK.

Georges Mayeux (G)

CEN Biotech, Dijon, Bourgogne Franche-Comté, France.

Florian Rigaudier (F)

CEN Biotech, Dijon, Bourgogne Franche-Comté, France.

Pierre Chauvelot (P)

CEN Biotech, Dijon, Bourgogne Franche-Comté, France.

Ludovic Robilliart (L)

CEN Biotech, Dijon, Bourgogne Franche-Comté, France.

Christine Juhel (C)

CEN Biotech, Dijon, Bourgogne Franche-Comté, France.

Yann Lecomte (Y)

CEN Biotech, Dijon, Bourgogne Franche-Comté, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH